304am永利集团|·主頁(歡迎您)

Be the most trusted biotech company

2024-01-05

Cancer Cell Published the Results of ASTRUM-004: HANSIZHUANG Combined with Chemotherapy for the First-line Treatment of sqNSCLC
2024-01-03

Henlius to Release Clinical Data at 2024 ASCO GI
2024-01-02

Expanded Access Policy for HLX42
2023-12-28

HANSIZHUANG Sets Sail in Indonesia Market
2023-12-27

FDA Grants Fast Track Designation to Henlius’ EGFR-Targeting ADC HLX42 for NSCLC Patients with Disease Progression on EGFR Targeted Therapies
2023-12-22

Henlius Passes Its Second EU GMP Inspection
2023-12-13

First Subject Dosed for Phase 1 Clinical Trial of Henlius’ Ipilimumab Biosimilar HLX13
2023-12-12

The NDA for New Indication of Henlius Anti-PD-1 mAb Serplulimab in Combination with Chemotherapy for the First-line Treatment of non-squamous NSCLC Accepted by the NMPA
2023-12-05

Henlius Receives "Listed Enterprises 2023" Award from Bloomberg Businessweek/Chinese Edition